T1	Outcomes 175 194	Safety and efficacy
T2	Outcomes 724 753	was time to progression (TtP)
T3	Outcomes 776 862	evaluated overall response rate (ORR), overall survival (OS), and adverse events (AEs)
T4	Outcomes 1157 1164	0.009).
T5	Outcomes 1250 1253	and
T6	Outcomes 1351 1354	CD.
T7	Outcomes 1454 1461	40.8%).
T8	Outcomes 1462 1474	TtP, OS, and
T9	Outcomes 1550 1645	greater fatigue, hepatotoxicity, neutropenia, and thrombocytopenia but not febrile neutropenia;
T10	Outcomes 1656 1721	more hand-foot syndrome, gastrointestinal toxicity, and mucositis
T11	Outcomes 1754 1783	similar efficacy and toxicity
